Forum Agenda

July 23,09:00-12:00

R&D Strategies for Developing Innovative Drug Molecules Session

Stay tuned

09:00-09:15 Integrated Solutions for Oligonucleotide Therapeutic Development
Haiying He: Vice President, Head of Oligonucleotide & Peptide Discovery Chemistry, WuXi TIDES

 

09:15-09:30 Bioanalytical Strategies for Pharmacokinetic Assessment of Oligonucleotide Therapeutics
Jinlian Lu: Director, Drug Metabolism and Pharmacokinetics (DMPK), Laboratory Testing Division (LTD), WuXi AppTec

 

09:30-09:45 CNS Delivery Technologies in Large Animal (Non-Rodent) Species Enable DMPK Studies of Oligonucleotide Therapeutics
Jie Li: Associate Director, Drug Metabolism and Pharmacokinetics (DMPK), Laboratory Testing Division (LTD), WuXi AppTec

 

09:45-10:00 Nonclinical Safety Evaluation of Oligonucleotide Drugs
Yan Zhang: Director, Toxicology, Laboratory Testing Division (LTD), WuXi AppTec

 

10:00-10:15 Challenges and Solutions in Clinical Bioanalysis of Novel Oligonucleotide Drugs
Wenzhong Liang: Executive Director, Bioanalysis, Laboratory Testing Division (LTD), WuXi AppTec

 

10:15-10:30 Coffee Break

 

10:30-10:45 Efficient Synthesis Strategies for TPD
Anshu Wu: Senior Director, Research Chemistry Services, WuXi Chemistry, WuXi AppTec

 

10:45-11:00 Key Points and Safety Evaluation in Nonclinical Design of TPD
Robert Zhang: Vice President, Head of Toxicology, Laboratory Testing Division (LTD), WuXi AppTec

 

11:00-11:15 Integrated Solutions for PROTAC Development
Yu Lu: Vice President of API Early Phase Process R&D, WuXi STA

 

11:15-12:00 Roundtable
TBD (More guests to be confirmed…)